{
    "clinical_study": {
        "@rank": "31659", 
        "arm_group": {
            "arm_group_label": "Psoriasis Plaque Test", 
            "arm_group_type": "Experimental", 
            "description": "SPS4251 Ointment, 0.01%; SPS4251 Ointment, 0.1%; SPS4251 Ointment, 1%; SPS4251 Placebo, Daivonex\u00ae ointment"
        }, 
        "brief_summary": {
            "textblock": "The current most important topical treatments for psoriasis are vitamin D3 analogues and/or\n      corticosteroids. The possibility of another effective treatment for psoriasis could be based\n      on the immunosuppressive efficacy of selective blockers of a lymphocyte potassium channel.\n\n      The aim of the clinical trial is to evaluate the safety, tolerability and anti-psoriatic\n      efficacy of topical SPS4251 formulations in comparison to placebo and to a marketed topical\n      Vitamin-D analogue ointment in a psoriasis plaque test."
        }, 
        "brief_title": "Antipsoriatic Effect of a Topical Formulation for the Treatment of Psoriasis Vulgaris", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Psoriasis Vulgaris", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  men aged 18 years or older\n\n          -  subjects with mild to moderate psoriasis vulgaris in a chronic stable phase\n\n          -  subject with up to three stable plaques with an area sufficient for five treatment\n             fields\n\n          -  Plaques to be treated should have a comparable thickness of the Echo Lucent Band of\n             at least 200 \u00b5m\n\n        Exclusion Criteria:\n\n          -  Subjects with guttate psoriasis, punctate psoriasis, erythrodermic psoriasis,\n             psoriatic arthropathy and pustular psoriasis\n\n          -  Local treatment with antipsoriatics in the 4 weeks preceding and/or during the trial,\n             and any topical antipsoriatic treatment on the plaques to be treated in this trial in\n             the 8 weeks before first treatment and/or during the trial\n\n          -  Systemic treatment with antipsoriatics e.g. corticosteroids, cytostatics, retinoids\n             in the three months before first treatment and during the trial;\n\n          -  Treatment with systemic medications or medications acting locally which might have\n             countered or influenced the trial aim\n\n          -  Contraindications according to summary of product characteristics of Daivonex\u00ae\n             Ointment;\n\n          -  UV-therapy within four weeks before first treatment and during the trial\n\n          -  Symptoms of a clinically significant illness that may influence the outcome of the\n             trial in the four weeks before baseline visit and during the trial\n\n          -  Any history of cardiovascular disease\n\n          -  Any evidence of ECG abnormality on screening ECG\n\n          -  Close affiliation with the Investigator (e.g. a close relative) or persons working at\n             bioskin GmbH or subject is an employee of the Sponsor;\n\n          -  Subject is institutionalized because of legal or regulatory order."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01743118", 
            "org_study_id": "SP001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Psoriasis Plaque Test", 
                "description": "Approximately 200 \u00b5l of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)", 
                "intervention_name": "SPS4251 Ointment", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Psoriasis Plaque Test", 
                "description": "Approximately 200 \u00b5l of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Psoriasis Plaque Test", 
                "description": "Approximately 200 \u00b5l of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments).", 
                "intervention_name": "Daivonex\u00ae ointment", 
                "intervention_type": "Drug", 
                "other_name": "calcipotriol"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Calcipotriene"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 16, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "Bioskin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany"
                    }, 
                    "name": "Bioskin"
                }
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase Ib, Two-centre, Randomised, Observer-blind, Placebo- and Comparator Controlled Trial to Evaluate the Safety, Tolerability and Antipsoriatic Efficacy of Three Strengths of a Topical SPS4251 Formulation in a Psoriasis Plaque Test", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Evaluation of plaque thickness-reducing efficacy measured by 20 MHz sonography of psoriatic infiltrate", 
            "safety_issue": "No", 
            "time_frame": "Up to Day 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01743118"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Evaluation of anti-psoriatic efficacy by clinical assessment", 
                "safety_issue": "No", 
                "time_frame": "Up to day 12"
            }, 
            {
                "measure": "Number of subjects with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 12"
            }
        ], 
        "source": "Circassia Limited", 
        "sponsors": {
            "collaborator": {
                "agency": "Bioskin GmbH", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Circassia Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}